|
|
|
|
| LEADER |
01744nmm a2200385 u 4500 |
| 001 |
EB001871968 |
| 003 |
EBX01000000000000001035339 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
190824 ||| eng |
| 100 |
1 |
|
|a Shah, Dhaval K.
|
| 245 |
0 |
0 |
|a Modeling of antibody-drug conjugate pharmacokinetics
|h Elektronische Ressource
|c Dhaval K. Shah
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2019, 2019
|
| 300 |
|
|
|a 1 streaming video file (49 min.)
|b color, sound
|
| 505 |
0 |
|
|a Antibody drug conjugates (ADCs) and their uses -- Different ways to measure ADCs in the cell -- Typical ADC PK in cells -- Modeling the cellular PK of ADCs -- Modeling the tumor PK of ADCs -- 7 steps -- Modeling whole-body PK of ADCs -- Combining PK and PD models -- Kadcyla case study
|
| 653 |
|
|
|a Immunoconjugates / pharmacology
|
| 653 |
|
|
|a Immunoconjugates / pharmacokinetics
|
| 653 |
|
|
|a Trastuzumab
|
| 653 |
|
|
|a Drug Discovery / methods
|
| 653 |
|
|
|a Drug Design
|
| 653 |
|
|
|a Antineoplastic Agents / therapeutic use
|
| 653 |
|
|
|a Antibodies, Monoclonal / pharmacokinetics
|
| 653 |
|
|
|a Computer Simulation
|
| 653 |
|
|
|a Models, Biological
|
| 653 |
|
|
|a Antibody-drug conjugates
|
| 653 |
|
|
|a Antineoplastic agents
|
| 653 |
|
|
|a Maytansine
|
| 653 |
|
|
|a Drug development
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Periodic reports : advances in clinical interventions and research platforms
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1048
|3 Series
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/3983
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|